Roche’s Rituxan Cures Rare Skin-Blistering Disease in Study

Published: Wednesday, March 6th 2013

(Bloomberg) - Roche Holding AG (ROG)’s top-selling drug Rituxan effectively cured most cases of a rare and deadly skin disease in a patient study that suggests the medicine may replace steroids as the standard treatment.

Read more.

Comment(s)

Your comments are valuable to us. Thank you.

Roche Reports Positive Data for MabThera Follow-On

Roche's Avastin Misses Key Data Point in Brain Cancer Study

Pioneering Study Will Test if Trio of Roche, Lilly Drugs Can Prevent Alzheimer's

Celgene's Abraxane Delivers in Melanoma Study

Experimental Roche Drug Shows Promise in Reducing Heart Damage